Hubbard S M, Longo D L
National Cancer Institute, Bethesda, Maryland.
Curr Opin Oncol. 1991 Oct;3(5):852-62. doi: 10.1097/00001622-199110000-00008.
The evolution of effective therapies for lymphoma has led to cures for many patients. In addition to the acute morbidity associated with cytotoxic therapy, significant delayed treatment-related effects have been identified. Complications include immunologic, cardiovascular, pulmonary, thyroid, and gonadal dysfunction as well as the development of second neoplasms. These complications results from tissue injury caused by the administration of radiation or chemotherapy, persistent immunologic deficits related to the underlying malignancy or its therapy, and complications of surgical staging and splenectomy. Disease or treatment-related immunosuppression and the mutagenic effects of therapy appear to predispose these patients to an increased risk of second cancers. This article reviews data from the recently published literature on these issues.
淋巴瘤有效治疗方法的演变已使许多患者得以治愈。除了与细胞毒性疗法相关的急性发病率外，还发现了显著的延迟治疗相关效应。并发症包括免疫、心血管、肺部、甲状腺和性腺功能障碍以及第二肿瘤的发生。这些并发症是由放疗或化疗给药引起的组织损伤、与潜在恶性肿瘤或其治疗相关的持续免疫缺陷以及手术分期和脾切除术的并发症导致的。疾病或治疗相关的免疫抑制以及治疗的诱变作用似乎使这些患者患第二癌症的风险增加。本文综述了最近发表的关于这些问题的文献数据。
